- On Monday, the Supreme Court followed the Solicitor General's advice and denied certiorari in Joblove v. Barr Labs, which concerned the legality of a "reverse payment" settlement of Hatch-Waxman litigation. Last year, the Court denied certiorari in a similar case, FTC v. Schering. Dow Jones reports that the FTC has vowed to press forward in its campaign against reverse payment settlements.
- Synthon and Teva announced this week that the FDA granted final approval to their ANDAs for generic Norvasc (amlodipine besylate). They join Mylan, which launched in March, and Apotex, which launched in May.
- FDA Law Blog reported earlier this week on an interesting new paper examining the regulatory challenges facing drug/device combination products.
Editor
About
- The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.
Disclaimer
- Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.
Susbscribe
« Federal Circuit Affirms Validity of Takeda's ACTOS Patent, Rejecting Alphapharm's Obviousness Arguments | Main | ACI "FDA Boot Camp" Conference, Boston, July 17-18 »
June 29, 2007
The comments to this entry are closed.
Susbscribe
Search
Categories
- 180-Day Exclusivity (26)
- 271(e)(1) Safe Harbor (11)
- 271(e)(2) Jurisdiction (2)
- 30-Month Stay (3)
- Antitrust (49)
- Authorized Generics (20)
- Biosimilars (33)
- Citizen Petitions (22)
- Claim Construction (1)
- Claim Preclusion (1)
- Collateral Estoppel (2)
- Conferences (92)
- Declaratory Judgment Jurisdiction (25)
- FDA Announcements (7)
- FDA Litigation (12)
- Inequitable Conduct (4)
- Infringement--271(g) (1)
- Infringement--Direct (4)
- Infringement--Indirect (7)
- Inter Partes Review (6)
- Issue Preclusion (2)
- Orange Book Issues (27)
- Paragraph IV Cases (207)
- Patent Eligibility (2)
- Patent Term Extension (13)
- Pediatric Exclusivity (14)
- Pharma Business News (38)
- Preliminary Injunction (2)
- Prosecution (1)
- Section viii Statements (5)
- Validity--Novelty (6)
- Validity--Obviousness (22)
- Validity--Section 101 (2)
- Validity--Section 112 (6)
Comments